VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Ruxolitinib for treatment of CRS in R/R AML treated with flotetuzumab

John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, outlines the results of a study investigating prophylactic ruxolitinib for the treatment of cytokine release syndrome (CRS) in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with flotetuzumab. The study found that prophylactic ruxolitinib produced a clear difference in cytokine profiles but no discernible improvement in clinical CRS or response rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter